Researchers Seek Answers to Painful Diseases with Painless Technology

Researchers investigating new approaches to Rheumatoid Arthritis have turned to new technology that is painless, non-invasive and easy to use to help measure the effect of different drug regimens and treatments in treating rheumatoid arthritis.

Trials from two studies conducted in India were published recently in the American Journal of Rheumatology. The group of researchers responsible for both studies used a device known as AngioDefender in their trials to accurately measure the effect of different medical approaches.

One Indian study investigated the use of stem cells in mitigating the cardiovascular risk of patients with Rheumatoid Arthritis. This is important because patients suffering from inflammatory disease are at a 50% higher risk of cardiovascular disease because their arterial system has been compromised 

The second study reported on the effect of Spironolactone as a novel disease modifying drug in Rheumatoid arthritis.

The AngioDefender medical device measures the function of endothelial cells- a single layer of cells that line the arteries of the vascular system. These cells control the muscles surrounding the arteries which determine the flexibility of the arterial walls. This turn has long been recognized as the best measure of cardiovascular health, and cardiovascular health is at the core of a whole range of important diseases including diabetes, kidney disease and inflammatory disease such as Rheumatoid Arthritis.

The beauty of the new technology is that it is noninvasive, painless, easy-to-use (even in a non-hospital setting) and uses a standard blood pressure cuff to carry out a series of measurements of the brachial artery in a subjects arm.

The Indian Rheumatoid Arthritis scientists who were the first to recognize the research potential of the AngioDefender test were from Punjabi University, Patiala and Healing Touch Clinic, Fortis Specialty Hospital, and Chandigarh India. The investigating researchers were Inderjeet Varma, Pawan Krishan and Ashit Syngle.

“These scientists are to be congratulated on their innovative approach to finding new ways to measure and evaluate different treatment options,” says Matt Bartlam, COO of Everist Health. “We believe more researchers around the world will follow their lead. They will find that our technology is affordable as well as effective and we welcome inquiries from the research community, in particular, scientists investigating chronic diseases. “

Scientists interested in using AngioDefender in their research projects should contact Everist Health at This email address is being protected from spambots. You need JavaScript enabled to view it.

To contact the researchers mentioned above go to:

For details on the research conducted by the Indian scientists, go to the American College of Rheumatology:

Read the abstract: 

Learn more about what we can do for you